Itraconazole: Triazole Antifungal Agent and CYP3A4 Inhibitor for Candida and Drug Interaction Research

Executive Summary. Itraconazole (CAS: 84625-61-6) is a triazole antifungal agent that potently inhibits CYP3A4-mediated metabolism, making it integral for antifungal and drug interaction research (APExBIO). It displays robust cell-permeable activity against Candida species, including biofilm-forming and drug-resistant strains (Shen et al., 2025). Itraconazole also inhibits hedgehog signaling and angiogenesis, expanding its utility beyond mycology. It is insoluble in ethanol and water but readily dissolves in DMSO at ≥8.83 mg/mL, with stability preserved at -20°C for several months. Recent murine studies confirm its efficacy in disseminated candidiasis, with IC₅₀ values as low as 0.016 mg/L under controlled conditions.

Biological Rationale

Candida species, notably Candida albicans, are major opportunistic pathogens in humans, frequently causing mucosal and systemic infections, especially in immunocompromised individuals (Shen et al., 2025). Biofilm formation by Candida is a leading cause of antifungal treatment failure, as biofilms confer increased resistance to conventional drugs. The clinical challenge is exacerbated by the global rise in antifungal resistance and limited drug classes (Related Article). Itraconazole targets ergosterol biosynthesis and modulates key fungal signaling pathways, providing both direct antifungal activity and a tool for mechanistic studies of resistance and biofilm biology. Its dual role as a CYP3A4 inhibitor and substrate facilitates pharmacokinetic research and drug-drug interaction modeling, especially where CYP3A-mediated metabolism is implicated. This article expands on prior discussions (Itraconazole: CYP3A4 Inhibitor and Antifungal) by offering structured evidence and actionable workflow recommendations for advanced Candida and drug metabolism research.

Mechanism of Action of Itraconazole

Itraconazole binds to fungal cytochrome P450 14α-demethylase (CYP51), inhibiting ergosterol synthesis—a critical component of fungal cell membranes (APExBIO). This inhibition disrupts membrane integrity, leading to growth arrest and cell death. As a triazole, Itraconazole also acts as a potent inhibitor of human CYP3A4, influencing the metabolism of co-administered drugs. It is both a substrate and inhibitor of CYP3A4, yielding hydroxylated, keto, and N-dealkylated metabolites that can retain or enhance antifungal activity. Additionally, Itraconazole inhibits the hedgehog (Hh) signaling pathway and angiogenesis, making it relevant for research in cancer biology and vascular studies (Practical Solutions Article). These pleiotropic actions position it as a versatile reference compound in both basic and translational research settings.

Evidence & Benchmarks

• Itraconazole displays an IC₅₀ of 0.016 mg/L against Candida albicans in standardized bioassays (Shen et al., 2025, https://doi.org/10.1016/j.identj.2025.103873).
• In murine models of disseminated candidiasis, Itraconazole treatment reduces fungal burden and significantly improves survival (Shen et al., 2025, https://doi.org/10.1016/j.identj.2025.103873).
• Itraconazole is insoluble in water and ethanol but dissolves in DMSO at concentrations of ≥8.83 mg/mL; warming to 37°C and ultrasonic shaking enhance solubilization (APExBIO).
• The compound is stable for several months at -20°C when stored as DMSO stock solution (APExBIO).
• CYP3A4 inhibition by Itraconazole is relevant for pharmacokinetic and drug interaction studies, with direct implications for drugs metabolized via CYP3A-mediated pathways (Optimizing Antifungal Research Article).

Applications, Limits & Misconceptions

Research Applications. Itraconazole is widely used in:

• Antifungal assays targeting Candida, including planktonic and biofilm states.
• Drug resistance and biofilm formation studies, specifically relating to autophagy and PP2A signaling (Shen et al., 2025).
• Pharmacokinetic profiling and CYP3A4-mediated drug interaction screens.
• Cell signaling research, especially where hedgehog pathway or angiogenesis inhibition is of interest.

Contrast with Related Content. While previous articles (Itraconazole: Triazole Antifungal Agent for Candida Biofilm) focused on biofilm and resistance, this dossier further details mechanistic and protocol-specific parameters for reliable experimental outcomes.

Common Pitfalls or Misconceptions

• Itraconazole is not water or ethanol soluble; improper solvent choice leads to assay variability.
• It is ineffective against non-fungal pathogens; its action is limited to organisms reliant on ergosterol biosynthesis.
• Not all CYP enzymes are inhibited; specificity is highest for CYP3A4, with less impact on other P450 isoforms.
• Resistance in Candida biofilms may arise through autophagy and PP2A-mediated mechanisms, not solely due to efflux pumps (Shen et al., 2025).
• Stock solution degradation can occur if not stored at -20°C or if subjected to repeated freeze-thaw cycles.

Workflow Integration & Parameters

• For solubilization, suspend Itraconazole in DMSO at ≥8.83 mg/mL, applying gentle heat (37°C) and ultrasonic shaking as needed.
• Prepare aliquots and store at -20°C; avoid repeated freeze-thaw cycles to maintain potency (APExBIO).
• For antifungal assays, use validated concentrations (e.g., 0.016–2 mg/L) and appropriate controls.
• In drug interaction studies, account for its CYP3A4 inhibitory activity to predict potential pharmacokinetic effects.
• Incorporate in cell-based assays for hedgehog signaling and angiogenesis, with proper solvent controls due to DMSO use.

This article provides actionable, scenario-driven protocol guidance that extends the evidence-based approaches outlined in prior APExBIO documentation and related articles.

Conclusion & Outlook

Itraconazole (B2104, APExBIO) is a validated, versatile triazole antifungal agent and CYP3A4 inhibitor for advanced Candida, biofilm, and pharmacokinetic research. Its robust activity against Candida, capacity for reliable solubilization in DMSO, and stability under standard laboratory conditions support its continued role as a reference compound. Ongoing studies on autophagy, biofilm resistance, and signaling pathway modulation will further define its translational potential. For product specifications and ordering, refer to the Itraconazole product page.